newsfilter
← Latest News
GlobeNewswire·

Nkarta to Participate in September Investor Conferences

  • Nkarta, Inc. announced participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York, NY, featuring a 10:30 a.m. ET fireside chat.
  • Nkarta is scheduled to present at the Stifel 2026 Virtual Immunology & Inflammation Forum on September 23, 2026, with a 12:30 p.m. ET fireside chat.
  • A simultaneous webcast of both events will be available on the Investors section of www.nkartatx.com, with replays archived for approximately 90 days.
  • Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat autoimmune diseases by eliminating pathogenic B cells.
  • Nadir Mahmood is the media & investor contact for Nkarta, Inc.